SG11201708692WA - Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof - Google Patents

Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof

Info

Publication number
SG11201708692WA
SG11201708692WA SG11201708692WA SG11201708692WA SG11201708692WA SG 11201708692W A SG11201708692W A SG 11201708692WA SG 11201708692W A SG11201708692W A SG 11201708692WA SG 11201708692W A SG11201708692W A SG 11201708692WA SG 11201708692W A SG11201708692W A SG 11201708692WA
Authority
SG
Singapore
Prior art keywords
thiadiazolidine
dioxide
preparation
salt form
crystal form
Prior art date
Application number
SG11201708692WA
Other languages
English (en)
Inventor
Peng Li
Bailing Yang
Fei Hao
Zheng Wang
Zongbin Li
Haiying He
Shuhui Chen
Wei Xiao
Wang Shen
Zhenzhong Wang
Original Assignee
Jiangsu Kanion Parmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Kanion Parmaceutical Co Ltd filed Critical Jiangsu Kanion Parmaceutical Co Ltd
Publication of SG11201708692WA publication Critical patent/SG11201708692WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B41/00—Formation or introduction of functional groups containing oxygen
    • C07B41/02—Formation or introduction of functional groups containing oxygen of hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
SG11201708692WA 2015-10-26 2016-10-25 Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof SG11201708692WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510703726 2015-10-26
PCT/CN2016/103297 WO2017071569A1 (zh) 2015-10-26 2016-10-25 1, 2, 5-噻二唑烷-1, 1-二氧化物的盐型、晶型及其制备方法和中间体

Publications (1)

Publication Number Publication Date
SG11201708692WA true SG11201708692WA (en) 2017-11-29

Family

ID=58629863

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708692WA SG11201708692WA (en) 2015-10-26 2016-10-25 Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof

Country Status (10)

Country Link
US (1) US10227339B2 (ko)
EP (1) EP3257851B1 (ko)
JP (1) JP6427695B2 (ko)
KR (1) KR102048391B1 (ko)
CN (1) CN107406439B (ko)
DK (1) DK3257851T3 (ko)
ES (1) ES2835061T3 (ko)
MY (1) MY174415A (ko)
SG (1) SG11201708692WA (ko)
WO (1) WO2017071569A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113940918B (zh) * 2020-07-17 2023-06-02 江苏康缘药业股份有限公司 一种药物组合物及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2658906A1 (de) * 1976-12-24 1978-07-06 Bayer Ag Beta-lactam-antibiotika, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
ZA846525B (en) * 1983-08-29 1985-04-24 Sterling Drug Inc (substituted)phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof
US5750546A (en) * 1994-12-02 1998-05-12 Sanofi Winthrop, Inc. 2-(2, 3, 5, 6-tetrafluoro-4-pyridyl)-1, 2, 5-thiadiazolidin-3-one 1, 1-dioxides and compositions and method of use thereof
US6706739B2 (en) * 2001-08-21 2004-03-16 National Health Research Institute Imidazolidinone compounds
US7129359B2 (en) * 2002-07-09 2006-10-31 National Health Research Institutes Imidazolidinone compounds
CN100999441A (zh) * 2006-01-13 2007-07-18 北京金源化学集团有限公司 红铝还原烷基丙二酸二酯为烷基－1,3－丙二醇
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
CN103351352B (zh) * 2013-07-15 2015-10-21 南通市华峰化工有限责任公司 一种5-苯基四氮唑新合成方法
CN104744433B (zh) * 2013-12-30 2016-09-21 中国科学院生物物理研究所 Ald及其作为ev71病毒和cav16病毒抑制剂的用途
GB201402169D0 (en) * 2014-02-07 2014-03-26 Isis Innovation Viral inhibitors
CN105085512A (zh) * 2014-04-28 2015-11-25 南京明德新药研发股份有限公司 抗肠病毒71噻二唑烷衍生物
WO2015165340A1 (zh) * 2014-04-28 2015-11-05 南京明德新药研发股份有限公司 抗肠病毒71噻二唑烷衍生物
US9988361B2 (en) * 2014-04-28 2018-06-05 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-enterovirus 71 thiadiazolidine derivative

Also Published As

Publication number Publication date
KR20170124597A (ko) 2017-11-10
JP6427695B2 (ja) 2018-11-21
EP3257851B1 (en) 2020-09-09
ES2835061T3 (es) 2021-06-21
DK3257851T3 (da) 2020-12-14
CN107406439A (zh) 2017-11-28
WO2017071569A1 (zh) 2017-05-04
JP2018509467A (ja) 2018-04-05
CN107406439B (zh) 2020-06-16
MY174415A (en) 2020-04-17
EP3257851A1 (en) 2017-12-20
KR102048391B1 (ko) 2020-01-08
EP3257851A4 (en) 2018-09-19
US20180141940A1 (en) 2018-05-24
US10227339B2 (en) 2019-03-12

Similar Documents

Publication Publication Date Title
EP3287444A4 (en) New crystal form of lenvatinib methanesulfonate salt and preparation method thereof
HK1254055A1 (zh) 製備奧貝膽酸及其衍生物的方法
PT3580219T (pt) Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam
GB201514760D0 (en) Compounds and method of use
PT3398598T (pt) Derivado de sulfonamida e método de preparação e utilização do mesmo
HK1256860A1 (zh) 喹唑啉衍生物的晶體及其製備方法
EP3502103A4 (en) CRYSTALLINE FORM, TYPE OF SALT OF A SUBSTITUTED 2-HYDRO-PYRAZOLE DERIVATIVE AND PREPARATION METHOD THEREOF
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
ZA201902628B (en) Non-solvated crystal, preparation method and application thereof
EP3239149A4 (en) Crystal form i of canagliflozin and preparation method thereof
SI3327012T1 (sl) Kristalinične oblike bilastina in postopki za pripravo le-teh
IL254709A0 (en) Methods for the use and production of innovative and useful salt for food
PL3330267T3 (pl) Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu
EP3310377A4 (en) Method of treating crohn's disease
EP3272751A4 (en) Crystal form of ipi-145 and preparation method thereof
EP3269710A4 (en) Nintedanib diethanesulfonate salt crystal and preparation method and use thereof
HK1258757A1 (zh) 4H-吡唑並[1，5-α]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體
HK1252375A1 (zh) 喹唑啉衍生物的晶體及其製備方法
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
SG11201708692WA (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof
HK1232209A1 (zh) 製備 -乙酰氧基丙酸及其衍生物的方法
HK1226085A1 (zh) 一種網紅細胞生長因子及其製備方法和應用
PT3632909T (pt) Sal e forma cristalina de composto de andrografólido modificado e seu método de preparação
ZA201901120B (en) Crystal and salt of nitroimidazole, and manufacturing method thereof
ZA201901155B (en) Salt and crystal of diaza-benzofluorane compound